Aducanumab Completed Phase 1 Trials for Alzheimer's Disease (AD) Basic Science

IndicationsStatusPurposePhase
CompletedBasic Science1
clinicaltrials.gov IdentifierTitleDrugs
NCT02782975Absolute Bioavailability of a Single, Fixed Subcutaneous Dose of Aducanumab in Healthy Participants